

Supplementary file

Supplementary Table 1 Characteristics of patients included in this meta-analysis.

Study	N	HL	Other lymphoma	Disease status before CD30 CAR-T (PD)	Prior therapies Median (range)
Wang 2016	18	17 (94.4%)	1 with ALCL (5.6%)	100%	exceeded 10
Ramos 2017	9	7 (77.8%)	2 with ALCL (22.2%)	88.9%	NA
Ramos 2020	42	42 (100%)	0(0.0%)	NA	7 (2-23)
Voorhees 2022	27	27 (100%)	0(0.0%)	NA	8 (3-23)
Sang 2022	12	9 (75.0%)	1with AITL (8.3%),2with GZL (16.7%)	100%	14 (6-31)
Zhang 2022	6	5 (83.3%)	0(0.0%)	50%	NA
Tschernia 2023	23	20 (86.9%)	2 with-cell lymphoma (8.7%), 1with GZL (4.3%)	74%	7 (3-12)
Brudno 2021	21	20 (95.2%)	1 with ALCL (4.8%)	NA	7 (4-15)

NA=not available; HL=Hodgkin lymphoma; ALCL= anaplastic large cell lymphoma; AITL= angioimmunoblastic T-cell lymphoma; GZL= gray zone lymphoma; PD= progressive disease



Supplementary Table 2 Quality of the 8 studies assessed by MINORS.

Study	I	II	III	IV	V	VI	VII	VIII	Total
Chun-Meng Wang 2016	2	2	2	2	2	0	2	0	12
Carlos A. Ramos 2017	2	2	2	1	1	1	2	1	12
Carlos A. Ramos 2020	2	2	2	2	2	2	2	0	14
Timothy J. Voorhees 2022	2	2	2	2	2	2	2	0	14
Wei Sang 2022	2	2	2	2	2	1	2	0	13
Peiling Zhang 2022	2	2	2	2	1	1	2	0	12
Nicholas P Tschernia 2023	2	2	2	1	1	1	2	0	11
Jennifer N. Brudno 2021	2	2	2	2	2	2	2	1	15



Supplementary Table 3 OS and PFS after anti-CD30 CAR-T cell infusion.

Study	Median follow-up	PFS	OS
Chun-Meng Wang 2016	NA	The median PFS was 6 months	NA
Carlos A. Ramos 2017	NA	NA	NA
Carlos A. Ramos 2020	533 days	The 1-year PFS was 36%	The 1-year OS was 94%
Timothy J. Voorhees 2022	9.5 months	The median PFS was 352 days	The median OS was NR
Wei Sang 2022	21.5 months	The PFS was 45%	The OS was 70%
Peiling Zhang 2022	20.4 months	NR	NR
Nicholas P Tschernia 2023	NA	NA	NA
Jennifer N. Brudno 2021	NA	The median PFS was 13 weeks	The median OS was 134 weeks


NA= not available; NR= not reached; PFS= progression-free survival; OS= overall survival



Supplementary Figure 1 Result of publication bias: ORR (A) and CR (B).



Supplementary Figure 2 Result of publication bias: PR (A) and SD (B).



Supplementary Figure 3 Result of publication bias: PFS (A) and OS (B).